Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss:

- Biogen’s next shot at an Alzheimer’s treatment.

- Why companies can’t “muscle their way” into making new molecules.

- How NVIDIA could change drug development. 

- Moderna’s vaccine strategy

Companies discussed: LLY, NVO, GPCR, NVDA, DXCM, NVDA, BIIB, GEHC, MRNA, NVCR, VRTX

Host: Deidre Woollard

Guest: Karl Thiel

Producer: Ricky Mulvey

Engineer: Tim Sparks

Learn more about your ad choices. Visit megaphone.fm/adchoices